Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Cres Rodriguez

Internal Medicine Tampa, FL Medical Doctor

NPI 1740213628 CMS profile 169387

6919 N Dale Mabry Hwy Ste 100, Tampa, FL 33614

Open in the dashboard

General payments

$7,170

457 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Cres Rodriguez of Tampa, FL is reported in the CMS Open Payments database as having received $7,170 across 457 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $20 1
2021 General $1,669 109
2020 General $2,315 142
2019 General $3,165 205

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cres Rodriguez
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Cres Rodriguez were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Cres Rodriguez Internal Medicine median Middle half National median
2019 $3,165 $159 $48–$570 $163
2020 $2,315 $119 $33–$402 $114
2021 $1,669 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $20 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Kowa Pharmaceuticals America, Inc. $1,376 105 payments
  2. Novo Nordisk Inc $1,055 70 payments
  3. AstraZeneca Pharmaceuticals LP $998 57 payments
  4. Amarin Pharma Inc. $573 50 payments
  5. AbbVie, Inc. $360 20 payments
  6. GlaxoSmithKline, LLC. $329 26 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $320 16 payments
  8. Astellas Pharma US Inc $294 13 payments
  9. Sanofi-Aventis U.S. LLC $292 17 payments
  10. Janssen Pharmaceuticals, Inc $260 12 payments
  11. Other $1,312 71 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $7,105 456 payments
  2. Education $65 1 payment
Products named General payments · program years 2019–2023
  1. Livalo $1,376 105 payments
  2. Bystolic $1,352 102 payments
  3. Ozempic $771 54 payments
  4. FARXIGA $517 29 payments
  5. Vascepa $404 30 payments
  6. RYBELSUS $386 33 payments
  7. CREON $320 18 payments
  8. Tresiba $283 16 payments
  9. SYMBICORT $276 13 payments
  10. XARELTO $260 12 payments
  11. Other $3,891 228 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 132 drugs

Part D claims

7,833

Median for Internal Medicine: 777

Drug cost

$809,279

Median for Internal Medicine: $73,373

Branded share of claims

18.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 71 $95,390
Farxiga Dapagliflozin Propanediol Brand 78 $94,873
Mounjaro Tirzepatide Brand 55 $86,299
Eliquis Apixaban Brand 38 $45,362
Jardiance Empagliflozin Brand 29 $41,565
Janumet Sitagliptin Phos/Metformin Hcl Brand 38 $40,988
Prolia Denosumab Brand 20 $34,615
Januvia Sitagliptin Phosphate Brand 33 $33,662
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 35 $32,443
Tresiba Flextouch U-200 Insulin Degludec Brand 27 $32,276

The 10 drugs with the highest cost, of 132 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$22,218

Medicare's payments for the services billed

Medicare patients

101

Average age 78

Services billed

366

46 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Chronic kidney disease 52%
Ischemic heart disease 37%
Diabetes 29%
Depression 25%
Osteoporosis 22%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

457 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record